PRESS RELEASES

Date Title and Summary View
Toggle Summary GlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple Myeloma
Trial to test candidate for second blood cancer type among patients responding poorly to standard therapy ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. ( NASDAQ : GLYC) today announced it has dosed its first patient in a Phase 1 clinical trial of its novel E-selectin antagonist, GMI-1271,
View HTML
Toggle Summary Glycomimetics Joins New Sickle Cell Disease Coalition, Issues Call to Action to Improve Treatment and Care
Glycomimetics Joins New Sickle Cell Disease Coalition, Issues Call to Action to Improve Treatment and Care
View HTML
Toggle Summary GlycoMimetics Initiates Dosing in Phase 1 Clinical Trial of GMI-1359
First-in-Humans Study of Third GlycoMimetics Drug Candidate ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. ( NASDAQ : GLYC) today announced dosing of the first healthy volunteers in a new Phase 1 clinical trial evaluating its novel combined E-selectin and CXCR4 antagonist GMI-1359.
View HTML
Toggle Summary GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack
Research shows effectiveness in stabilizing atherosclerotic plaques, reducing risk of further injury due to reduced blood flow ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. ( NASDAQ : GLYC) today announced the publication of results from a preclinical study that showed its drug candidate
View HTML
Toggle Summary GlycoMimetics to Present at Canaccord Genuity 36th Annual Growth Conference
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at Canaccord Genuity 36th Annual Growth Conference in Boston , on Thursday, August 11, 2016 2:30 p.m. ET .
View HTML
Toggle Summary GlycoMimetics Reports Second Quarter 2016 Results
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. ( NASDAQ : GLYC) today reported financial results for the second quarter and six months ended June 30, 2016 . "For GlycoMimetics, the second quarter was highlighted by both financial and clinical achievements.
View HTML
Toggle Summary GlycoMimetics Doses First Patient in Phase 2 Portion of Clinical Trial of GMI-1271 in Newly Diagnosed Acute Myeloid Leukemia
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. ( NASDAQ : GLYC) today announced dosing of the first patient with newly diagnosed acute myeloid leukemia (AML) in the Phase 2 portion of its ongoing Phase 1/2 study evaluating its novel E-selectin antagonist, GMI-1271, combined with
View HTML
Toggle Summary GlycoMimetics Announces Pricing of Public Offering of Common Stock
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. ( NASDAQ : GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 3,300,000 shares of its common stock at a price to
View HTML
Toggle Summary GlycoMimetics Announces Proposed Public Offering of Common Stock
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. ( NASDAQ : GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an
View HTML
Toggle Summary GlycoMimetics' GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel E-selectin antagonist GMI-1271 for treatment of adult patients with relapsed or refractory acute myeloid
View HTML